Belgium OBJECTIVE: To compare the evolution of persistence rates and drug costs in patients whose antihypertensive therapy was started with a low-dose combination therapy or with various monotherapies in daily practice. METHODS: Patients in the Thalès database in France, whose therapy was started with 1) a low-dose combination of bisoprolol and hydrochlorothiazide (b/hctz); 2) angiotensin-II-antagonists (AIIA); 3) calcium-channel blockers (CCB); or 4) angiotensin-converting enzyme inhibitors (ACE) from January-August 2000, were followed up for 1.5 years. The prescriptions at inclusion and the final prescriptions in each subsequent quarter were recorded. Patients who remained on their initial treatment were classified as persistent. The average daily drug costs per patient (ADDC) were calculated for all four groups at all measurement points based on public prices in France. RESULTS: A total of 1587 patients were included. The persistence rate at study end was 68.3% in the low-dose b/hctz group, followed by the AIIA (57.2%), the CCB (56.1%) and the ACE group (51.7%). Statistical significance was only reached between the b/hctz group and the ACE group (p < 0.01). Switches in therapy and the initiation of combination treatments led to a steady increase in ADDC in the CCB, ACE and b/hctz groups during follow-up (from 0.66€ to 0.90€, 0.76€ to 0.86€ and 0.45€ to 0.60€, respectively). In the AIIA group, ADDC decreased slightly due to switches in therapy to lowerpriced drugs (1.08€ to 1.03€). Pairwise differences in ADDC between the b/hctz group and all other groups reached significance at all measurement points (p < 0.01). CONCLUSION: Frequent changes in treatment make it difficult to predict the evolution of daily drug costs in hypertension. In our study, the ADDC in the b/hctz group were lower than in the three comparator groups at inclusion and remained lower after the effect of treatment changes were taken into account. To compare the costs of hypertension in Poland, measured from the third party payer perspective and the societal perspective. METHODS: The retrospective analysis of the 9286 patients' records derived from a scientific project conducted among GPs' in the whole of Poland in the year 2000. The time horizon was 12 months. Calculations were made from the thirdparty payer perspective including costs of: drug reimbursement, physicians' consultations, laboratory, diagnostic tests and hospitalisation. The unit costs were obtained from the Polish National Health Fund. Calculations from the societal perspective were also made to evaluate patient expenditure on drugs and indirect costs. RESULTS: Direct medical costs constituted 59% of the total hypertension costs in Poland (214€ per patient per year), 16% of which represented the cost of pharmacological treatment. Indirect costs (41%) amounted to 148€ per patient per year. Assuming that 8.5 million Poles suffer from hypertension, the total societal burden of hypertension could reach 1.53€ billion annually. From the third-party payer perspective, distribution of the costs was as follows: laboratory and diagnostic tests 21%, hospitalization 31%, physicians' consultations, 37% and drugs only 11%, because of an extremely high patient copayment rate of 67%. The total, annual third party payer burden of hypertension amounted to 723€ million (172€ per patient), which equalled 47.5% of the total societal costs, including indirect costs. Assuming 400,000 new cases of hypertension annually, total costs related to the incidence of hypertension in Poland could reach 65.7€ million. CONCLUSION: The costs of hypertension impact on the third party payer and Polish society to the same extent. High patient co-payment for antihypertensive drugs and a relatively low reimbursement rate, lead to limited access to innovative therapies, which may cause a gradual increase in hypertension costs in Poland in the future.
PCV17 COSTS OF HYPERTENSION IN POLAND MEASURED FROM THE THIRD PARTY PAYER PERSPECTIVE IN COMPARISON WITH THE SOCIETAL PERSPECTIVE
Hermanowski T 1 , Jaworski R 2 , Czech M 2 , Pachocki R 2 1 Warsaw University of Technology, Warsaw, Poland; 2 Servier Polska, Warsaw, Poland OBJECTIVE: To compare the costs of hypertension in Poland, measured from the third party payer perspective and the societal perspective. METHODS: The retrospective analysis of the 9286 patients' records derived from a scientific project conducted among GPs' in the whole of Poland in the year 2000. The time horizon was 12 months. Calculations were made from the thirdparty payer perspective including costs of: drug reimbursement, physicians' consultations, laboratory, diagnostic tests and hospitalisation. The unit costs were obtained from the Polish National Health Fund. Calculations from the societal perspective were also made to evaluate patient expenditure on drugs and indirect costs. RESULTS: Direct medical costs constituted 59% of the total hypertension costs in Poland (214€ per patient per year), 16% of which represented the cost of pharmacological treatment. Indirect costs (41%) amounted to 148€ per patient per year. Assuming that 8.5 million Poles suffer from hypertension, the total societal burden of hypertension could reach 1.53€ billion annually. From the third-party payer perspective, distribution of the costs was as follows: laboratory and diagnostic tests 21%, hospitalization 31%, physicians' consultations, 37% and drugs only 11%, because of an extremely high patient copayment rate of 67%. The total, annual third party payer burden of hypertension amounted to 723€ million (172€ per patient), which equalled 47.5% of the total societal costs, including indirect costs. Assuming 400,000 new cases of hypertension annually, total costs related to the incidence of hypertension in Poland could reach 65.7€ million. CONCLUSION: The costs of hypertension impact on the third party payer and Polish society to the same extent. High patient co-payment for antihypertensive drugs and a relatively low reimbursement rate, lead to limited access to innovative therapies, which may cause a gradual increase in hypertension costs in Poland in the future. To compare the costs of hypertension in the elderly with the costs in patients under 65 in Poland. METHODS: The time horizon of the analysis was 12 months and a retrospective approach was applied. Calculations were made from the societal perspective. Direct medical costs of pharmacological treatment, physicians' consultations, laboratory, diagnostic tests and hospitalisation were identified and calculated. Indirect costs resulting from productivity loss were also included in the analysis. Resource utilisation data were derived from a scientific project conducted among GPs' in the whole of Poland in the year 2000. The unit costs were obtained from the Polish National Health Fund. RESULTS: The total annual direct medical cost per patient in the elderly group was 15% higher than in the group of patients under 65 and was equal to 239€. The distribution of the direct medical costs in the elderly group was as follows: drugs 25%, physicians' consultations 28%, laboratory, diagnostic tests 21% and hospitalisation 25%. Both physicians' consultation costs (68€ per patient per year) and hospitalisation costs (61€ per patient per year) were higher in elderly group than in younger patients (45% and 12% respectively). The indirect costs for elderly patients were about ten times lower than in patients under 65, which generated the costs of 214€ per patient per year. CONCLUSION: The direct medical costs were higher in elderly hypertensive patients. The indirect costs were higher in younger hypertensive probably due to retirement at 60 for women and 65 for men in Poland. There are no differences between the compared groups in expenditure on drugs and patients' co-payment. The trends observed may have a great impact on the total burden of hypertension, because of the higher incidence of hypertension in younger people and the aging of the Polish population. 
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